Contact Us

No Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Please describe your case:

Date of Incident : 

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Cox-II Inhibitors


COX II Inhibitors Side Effects May Lead To Heart Attack Lawsuits

COX II inhibitors | Lawsuits, Lawyers | Side Effects: Cardiovascular Events, Heart Attack, Strokes

COX II inhibitors are a relatively new family of nonsteroidal anti-inflammatory drugs ( NSAIDS). There is a controversy surrounding the use of COX II inhibitors. Scientists believe that their use is associated with an increased risk of cardiovascular events such as heart attack and stroke.

All NSAID drugs (even the newer ones like Vioxx and Bextra) cause irritation, ulceration, bleeding and perforation of the lining of the stomach and blood clotting. Merck's aggressive promotional campaign quickly boosted Vioxx into the top 20 U.S. drugs. It has been among the drugs most heavily advertised to doctors and patients alike.

Vioxx users doubled their risk of heart attack and stroke, abruptly pulled the drug from the world market. Days later, the Wall Street Journal reported on an analysis never made public by a safety official at the U.S. Food and Drug Administration. The study, examining data on 1.4 million Kaiser Permanente members, drew this conclusion: More than 27,000 heart attacks and sudden cardiac deaths.

Bextra has been linked to Heart Attack, Stroke and Stevens Johnson Syndrome. Recent reports show that Bextra may be more likely to cause Heart Attacks and Stroke than Vioxx. Additionally, Pfizer has recenty said they will most likely add a black box warning to Bextra about Stevens Johnson Syndrome.

Bextra is a COX-2 inhibitor, marketed by Pharmacia Corporation and Pfizer Inc. in the United States. The drug is prescribed for the treatment of osteoarthritis, adult rheumatoid arthritis, and the pain associated with menstrual cramping.

Legal Help For Victims Affected By COX II Inhibitors

If you or a loved one took COX II Inhibitors and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


Cox-II InhibitorsRSS Feed

Study Links NSAIDs to Higher Risk of Death from Endometrial Cancer

Feb 6, 2017
Study Looks at Drugs Like Aspirin, Ibuprofen and Cancer-Related Death Patients who regularly use non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen may have a higher risk of dying from Type 1 endometrial cancers, a study published in the Journal of the National Cancer Institute suggests. Lead researchers from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) conducted a...

Painkillers, cholesterol linked

Feb 13, 2007 | Newsday
Certain pain-relieving drugs that belong to a group of medications called COX inhibitors may impair the ability of human blood cells to rid themselves of cholesterol, according to research published Jan. 23 in the journal Arthritis Research & Therapy. The finding suggests an explanation for an increased risk of heart attacks in people who used Vioxx and Bextra called COX-2 inhibitors and could help the pharmaceutical industry develop new arthritis pain drugs. The researchers, including...

New data noted on Vioxx risk

May 18, 2006 | UPI
The risk related to the painkiller Vioxx may begin earlier than what Merck & Co. has said, The Wall Street Journal reports, but the company doesn't agree. The Journal says new company data suggest the cardiovascular risk begins within four months of Vioxx use, and not 18 months as the company has said. The Journal cited a graph in a new one-year follow-up of patients. It said the graph tracking the number of "confirmed thrombotic cardiovascular events" indicated those occurring in Vioxx...

Merck data suggests earlier onset of Vioxx risks

May 18, 2006 |
New data from drug maker Merck suggests that heart risks associated with painkiller Vioxx begin much earlier than it had previously suggested, said a report published Thursday. The data suggest that cardiovascular risks increase for Vioxx users after four months of use, rather than 18 months as the company had previously said, according to the Wall Street Journal. Merck initially withdrew Vioxx from the market in September 2004, citing data from a study called Approve that showed an uptick in...

Doctors say Vioxx risks lingered a year after patients stopped use

May 13, 2006 | AP
People who took the painkiller Vioxx were at increased risk of heart attack and stroke for at least a year after they stopped taking the drug, several doctors said Friday, challenging claims the drug's maker had made a day earlier. The physicians disputed the interpretation of a study by Merck & Co., Vioxx's maker. Company officials had contended Thursday that Vioxx users weren't at increased risk of heart attack or stroke in the year after quitting the drug. "Merck misrepresented the...

More Cox-II Inhibitors News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo